We are live on
!
Find out more
BCM
Brooktree Capital Management Portfolio holdings
AUM
$126M
1-Year Est. Return
0.5%
This Fund
S&P 500
This Quarter
Est. Return
+34.31%
1 Year Est. Return
-0.5%
3 Year Est. Return
+57.3%
5 Year Est. Return
+44.35%
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$20M
(+23%)
Cap. Flow
-$1.78M
Cap. Flow
% of AUM
-1.67%
Top 10 Holdings %
Top 10 Hldgs %
55.13%
Holding
104
New
–
Increased
11
Reduced
29
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DXC Technology
DXC
|
+$820K |
| 2 |
PAR Technology
PAR
|
+$337K |
| 3 |
Interactive Brokers
IBKR
|
+$289K |
| 4 |
AbbVie
ABBV
|
+$120K |
| 5 |
CVET
Covetrus, Inc. Common Stock
CVET
|
+$76K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$325K |
| 2 |
Biogen
BIIB
|
+$259K |
| 3 |
RTX Corp
RTX
|
+$192K |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$121K |
| 5 |
Jefferies Financial Group
JEF
|
+$110K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.36% |
| 2 | Financials | 21.32% |
| 3 | Industrials | 15.68% |
| 4 | Healthcare | 15.17% |
| 5 | Consumer Discretionary | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
W.P. Carey
WPC
$17B
| – | – |
-306
| Closed | -$17K |
|
|
SRCL
102
DELISTED
Stericycle Inc
SRCL
| – | – |
-1,708
| Closed | -$83K |
|
|
AGN
103
DELISTED
Allergan plc
AGN
| – | – |
-1,836
| Closed | -$325K |
|
|
UN
104
DELISTED
Unilever NV New York Registry Shares
UN
| – | – |
-825
| Closed | -$40K |
|
Similar funds
BWA
CAM
BAM
BPW
GF
LGG
GC
BFS
Brooktree Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Brooktree Capital Management held 104 positions worth $106M, up 23% from $86.3M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Brooktree Capital Management's Q2 2020 filing shows 11 increased, 29 reduced and 57 closed positions. The largest sale was Allergan plc, an estimated $325K.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 26% a quarter earlier, followed by Financials and Industrials.
- Brooktree Capital Management added most to DXC Technology in Q2 2020, an estimated $820K increase.
- Brooktree Capital Management's biggest Q2 2020 reduction was RTX Corp, cutting an estimated $192K.
- Brooktree Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $325K.
- Brooktree Capital Management's ten largest holdings make up 55% of its $106M portfolio in Q2 2020.
- Brooktree Capital Management opened 0 new positions and closed 57 in Q2 2020.
- Brooktree Capital Management's portfolio value rose 23% quarter-over-quarter to $106M.
Based on Brooktree Capital Management's 13F filing for Q2 2020, filed 3 Aug 2020.